Cave cyanobacteria showing antibacterial activity

International Journal of Speleology

Volumn 44, Issue 3, 2015, Pages 231-238

  Lamprinou, Vasiliki ^a   Tryfinopoulou, Kyriaki ^b   Velonakis, Emmanuel N ^b,c   Vatopoulos, Alkiviadis ^b,c   Antonopoulou, Smaragdi ^d   Fragopoulou, Elizabeth ^d   Pantazidou, Adriani ^a   Economou Amilli, Athena ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Central Public Health Laboratory   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^d HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Antimicrobial susceptibility screening; Cave cyanobacteria; Phormidium melanochroun; Toxopsis calypsus

Indexed keywords

ANTIMICROBIAL ACTIVITY; CAVE DEPOSIT; CYANOBACTERIUM; INHIBITION; LIPID; MICROBIAL COMMUNITY; MICROBIOLOGY; PATHOGENICITY;

GREECE;

CYANOBACTERIA; NEGIBACTERIA; PHORMIDIUM; POSIBACTERIA;

EID: 84932631570     PISSN: 03926672     EISSN: 1827806X     Source Type: Journal    
DOI: 10.5038/1827-806X.44.3.2     Document Type: Article

References (52)

1. Abdel-Raouf A.N. & Ibraheem I.B.M., 2008. Antibiotic activity oftwo Anabaena species against fourfish pathogenic Aeromonas species. African Journal of Biotechnology, 15: 2644-2648.
2. Antonopoulou S., Oikonomou A., Karantonis H.C., Fragopoulou E. & Pantazidou A., 2002. Isolation and structure elucidation of biologically active phospholipids from Scytonema julianum (Cyanobacteria). Biochemical Journal, 367: 287-293. http://dx.doi.org/10.1042/BJ20020146
3. Antonopoulou S., Nomikos T., Oikonomou A., Kyriacou A., Andriotis M., Fragopoulou E. & Pantazidou A., 2005. Characterization of bioactive glycolipids from Scytonema julianum (Cyanobacteria). Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 140: 219-231. http://dx.doi.org/10.1016/j.cbpc.2004.10.006
4. Antonopoulou S., Karantonis H.C., Nomikos T., Oikonomou A., Fragopoulou E. & Pantazidou A., 2005. Bioactive polar lipids from Chroococcidiopsis sp. (Cyanobacteria). Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 142: 269-282.http://dx.doi.org/10.1016/j.cbpc.2005.07.007
5. Asthana R., Deepali A., Tripathi M., Srivastava A., Singh A., Singh S., Nath G., Srivastava R. & Srivastava B., 2009. Isolation and identification of a new antibacterial entity from the Antarctic cyanobacterium Nostoc CCC 537. Journal of Applied Phycology, 21: 81-88. http://dx.doi.org/10.1007/s10811-008-9328-2
6. Bligh E. & Dyer W.J., 1959. A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology, 37: 911-917. http://dx.doi.org/10.1139/o59-099
7. Borowitzka M., 1995. Microalgae as sources of pharmaceuticals and other biologically active compounds. Journal of Applied Phycology, 7: 3-15. http://dx.doi.org/10.1007/BF00003544
8. Burja A.M., Banaigs B., Abou-Mansour E., Grant Burgess J. & Wright P.C., 2001. Marine cyanobacteria. A prolific source of natural products. Tetrahedron, 57: 9347-9377. http://dx.doi.org/10.1016/S0040-4020(01)00931-0
9. Chang C.C., Chen W.C., Ho T.F., Wu H.S. & Wei Y.H., 2011. Development of natural anti-tumor drugs by microorganisms. Journal of Bioscience and Bioengineering, 111: 501-511. http://dx.doi.org/10.1016/j.jbiosc.2010.12.026
10. CLSI, 2012. Performance standards for antimicrobial susceptibility testing. Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute.
11. Dapkevicius MdLNE, 2013. Cave biofilms and their potential for novel antibiotic discovery. In: Cheeptham N. (Ed.), Cave microbiomes: A novel resource for drug discovery. Springer Briefs in Microbiology. Springer, New York, p. 35-44.
12. Desbois A.P. & Smith V.J., 2010. Antibacterial free fatty acids: Activities, mechanisms ofaction and biotechnological potential. Applied Microbiology and Biotechnology, 85: 1629-1642. http://dx.doi.org/10.1007/s00253-009-2355-3
13. Dobretsov S., Abed R.M.M., Maskari S., Sabahi J. & Victor R., 2011. Cyanobacterial mats from hot springs produce antimicrobial compounds and quorum-sensing inhibitors under natural conditions. Journal of Applied Phycology, 23: 983-993. http://dx.doi.org/10.1007/s10811-010-9627-2
14. Engene N., Coates R.C. & Gerwick W.H., 2010. 16S rRNA gene heterogeneity in the filamentous marine cyanobacterial genus Lyngbya. Journal of Phycology, 46: 591-601. http://dx.doi.org/10.1111/j.1529-8817.2010.00840.x
15. Engene N., Rottacker E.C., Kastovsky J.H., Byrum T., Choi H., Komârek J. & Gerwick W.H., 2012. Moorea producens gen. nov., sp. nov. and Moorea bouillonii comb. nov., tropical marine cyanobacteria rich in bioactive secondary metabolites. International Journal of Systematic and Evolutionary Microbiology, 62: 1172-1179. http://dx.doi.org/10.1099/ijs.0.033761-0
16. Engene N., Gunasekera S.P., Gerwick W.H. & Paul V.J., 2013. Phylogenetic inferences reveal a large extent of novel biodiversity in chemically rich tropical marine cyanobacteria. Applied and Environmental Microbiology, 79: 1882-1888. http://dx.doi.org/10.1128/AEM.03793-12
17. Galanos D.S. & Kapoulas V.M., 1962. Isolation of polar lipids from triglyceride mixtures. Journal of Lipid Research, 3: 134-137.
18. Harvey A., 2000. Strategies for discovering drugs from previously unexplored natural products. Drug Discovery Today, 5: 294-300. http://dx.doi.org/10.1016/S1359-6446(00)01511-7
19. Hayashi T., Hayashi K., Maeda M. & Kojima I., 1996. Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platensis. Journal of Natural Products, 59: 83-87. http://dx.doi.org/10.1021/np960017o
20. IDSA (Infectious Diseases Society of America), 2007. Bad bugs, no drugs: as antibiotic discovery stagnates…a public health crisis brews. http://www.idsociety.org/uploadedFiles/IDSA/PolicyandAdvocacy/CurrentTopicsandIssues/AdvancingProductResearchandDevelopment/BadBugsNoDrugs/Statements/AsAntibioticDiscoveryStagnatesAPublicHealthCrisisBrews.pdf [accessed: January 3, 2007].
21. Kaushik P. & Chauhan A., 2008. In vitro antibacterial activity of laboratory grown culture of Spirulina platensis. Indian Journal of Microbiology, 48: 348-352. http://dx.doi.org/10.1007/s12088-008-0043-0
22. Kaushik P., Chauhan A., Chauhan G. & Goyal P., 2009. Antibacterial potential and UV-HPLC analysis of laboratory-grown culture of Anabaena variabilis. International Journal of Food Safety, 11: 11-18.
23. Khairy H.M. & El-Kassas H.Y., 2010. Active substance from some blue green algal species used as antimicrobial agents. African Journal of Biotechnology, 9: 2789-2800.
24. Komârek J., Zapomelovâ E., Smarda J., Kopecky J., Rejmânkovâ E., Woodhouse J., Neilan B.A. & Komârkovâ J., 2013. Polyphasic evaluation of Limnoraphis robusta, a water-bloom forming cyanobacterium from Lake Atitlan, Guatemala, with a description of Limnoraphis gen. nov. Fottea, 13: 39-52. http://dx.doi.org/10.5507/fot.2013.004
25. Kumar M., Tripathi M.K., Srivastava A., Nath G. & Asthana R.K., 2012. A comparative study of antibacterial activity of brackish and fresh water cyanobacterial strains. Asian Journal of Experimental Biological Sciences, 3: 548-552.
26. Lamprinou V., Skaraki K., Kotoulas G., Economou-Amilli A. & Pantazidou A., 2012. Toxopsis calypsus gen. nov., sp. nov. (Cyanobacteria, Nostocales) from cave 'Francthi', Peloponnese, Greece. Morphological and molecular evaluation. International Journal of Systematic and Evolutionary Microbiology, 62: 2870-2877. http://dx.doi.org/10.1099/ijs.0.038679-0
27. Lamprinou V., Skaraki K., Kotoulas G., Anagnostidis K., Economou-Amilli A. & Pantazidou A., 2013. A new species of Phormidium (Cyanobacteria, Oscillatoriales) from three Greek caves. Morphological and molecular analysis. Fundamental and Applied Limnology, 182: 109-116. http://dx.doi.org/10.1127/1863-9135/2013/0323
28. Luesh H., Moore R.E., Paul V.J., Mooberry S.L. & Corbett T.H., 2001. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP 642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. Journal of Natural Products, 64: 907-910. http://dx.doi.org/10.1021/np010049y
29. MacMillan J.B., Ernst-Russell M.A., De Ropp J.S. & Molinski T.F., 2002. Lobocyclamides A-C, lipopeptides from a cryptic cyanobacterium mat containing Lyngbya confervoides. Journal of Organic Chemistry, 67: 8210-8215. http://dx.doi.org/10.1021/jo0261909
30. Madhumathi V., Deepa P., Jeyachandran S., Manoharan C. & Vijayakumar S., 2011. Antimicrobial activity of cyanobacteria isolated from freshwater lake. International Journal of Microbiology Research, 3: 213-216.
31. Matthew S., Schupp P.J. & Luesch H., 2008. Apratoxin E, a cytotoxic peptolide from a Guamanian collection of the marine cyanobacterium Lyngbya bouillonii. Journal of Natural Products, 71: 1113-1116. http://dx.doi.org/10.1021/np700717s
32. Mian P., Heilmann J., Burgi H.R. & Sticher O., 2003. Biological screening of terrestrial and freshwater cyanobacteria for antimicrobial activity, brine shrimp lethality, and cytotoxicity. Pharmaceutical Biology, 4: 243-247. http://dx.doi.org/10.1076/phbi.4L4.243.15672
33. Montano E.T. & Henderson L.O., 2013. Studies of antibiotic production by cave bacteria. In: Cheeptham N. (Ed.), Cave Microbiomes: A novel resource for drug discovery. Springer Briefs in Microbiology, Springer New York, p. 109-130. http://dx.doi.org/10.1007/978-1-4614-5206-5 6
34. Mundt S., Kreitlow S., Nowonty A. & Effrmert U, 2001 Biological and pharmacological investigation of selected cyanobacteria. International Journal of Hygiene and Environmental Health, 203: 327-234. http://dx.doi.org/10.1078/1438-4639-00045
35. Mundt S., Kreitlow S. & Jansen R., 2003. Fatty acids with antibacterial activity from the cyanobacterium Oscillatoria redekei HUB 051. Journal of Applied Phycology, 15: 263-267. http://dx.doi.org/10.1023/A:1023889813697
36. Najdenski H.M., Gigova L.G., Iliev II., Pilarski P.S., Lukavsky J., Tsvetkova I.V., Ninova M.S. & Kussovski V.K., 2013. Antibacterial and antifungal activities of selected microalgae and cyanobacteria. International Journal of Food Science and Technology, 48: 1533-15440. http://dx.doi.org/10.1111/ijfs.12122
37. Nicolaus B., Karambourova M. & Oner E.T., 2010 Exopolysaccharides from extremophiles: from fundamentals to biotechnology. Environmental Technology, 31: 1145-1158. http://dx.doi.org/10.1080/09593330903552094
38. Ostensvik O., Skulberg O.M., Underdal B. & Hormazabal V., 1998. Antibacterial properties of extracts from selected planktonic freshwater cyanobacteria: A comparative study of bacterial bioassays. Journal of Applied Microbiology, 84: 117-124. http://dx.doi.org/10.1046/j.1365-2672.1998.00449.x
39. Papke U., Gross E.M. & Francke W., 1997. Isolation, identification and determination of the absolute configuration of fischerellin B. A new algicide from the fresh water cyanobacterium Fischerella muscicola (Thuret). Tetrahedron Letters, 38: 379-382. http://dx.doi.org/10.1016/S0040-4039(96)02284-8
40. Plaza M., Santoyo S., Jaime L., Garcîa-Blairsy Reina G., Herrero M., Senorâns F.J. & Ibânez E., 2010 Screening for bioactive compounds from algae. Journal of Pharmaceutical and Biomedical Analysis, 51: 450-455. http://dx.doi.org/10.1016/j.jpba.2009.03.016
41. Ramadan M.F., Asker M.M.S & Ibrahim Z.K, 2008 Functional bioactive compounds and biological activities of Spirulina platensis lipids. Czech Journal of Food Sciences, 3: 211-222.
42. Ramamurthy V., Raveendran S., Thirumeni S. & Krishnaveni S., 2012. Antimicrobial activity of heterocyte Cyanobacteria. International Journal of Advanced Life Sciences, 1: 32-39.
43. Sharp K., Arthur K., Gu L., Ross C., Harrison G., Gunasekera S.P., Meickle T., Matthew S., Luesch H., Thacker R.W., Sherman D.H. & Paul V.J., 2009. Phylogenetic and chemical diversity of three chemotypes of bloom-forming Lyngbya species (Cyanobacteria: Oscillatoriales) from reefs of south-eastern Florida. Applied and Environmental Microbiology, 75: 2879-2888. http://dx.doi.org/10.1128/AEM.02656-08
44. Seufferheld M., Alvarez H.M. & Farias M.E., 2008 Role ofpolyphosphates in microbial adaptation to extreme environments. Applied and Environmental Microbiology, 74: 5867-5874. http://dx.doi.org/10.1128/AEM.00501-08
45. Simmons T.L., Andrianasolo E., McPhail K., Flatt P. & Gerwick W.H., 2005. Marine natural products as anticancer drugs. Molecular Cancer Therapeutics, 4: 333-342.
46. Singh O.V. & Gabani P., 2011. Extremophiles: radiation resistance microbial reserves and therapeutic implications. Journal of Applied Microbiology, 110: 851-861. http://dx.doi.org/10.1111/j.1365-2672.2011.04971.x
47. Singh R.K., Tiwari S.P., Rai A.K. & Mohapatra T.M., 2011. Cyanobacteria: An emerging source for drug discovery. The Journal of Antibiotics, 64: 401-412. http://dx.doi.org/10.1038/ja.2011.21
48. Stanier R.Y., Kunisawa R., Mandel R. & Cohen-Bazire G., 1971. Purification and properties of unicellular blue green algae (Order Chroococcales). Bacteriological Reviews, 35: 171-205.
49. Suhail S., Biswas D., Farooqui A., Arif J.M. & Zeeshan M., 2011. Antibacterial and free radical scavenging potential of some cyanobacterial strains and their growth characteristics. Journal of Chemical and Pharmaceutical Research, 3: 472-478.
50. Uzair B., Tabassum S., Rashed M. & Rehman S.F., 2012. Exploring marine Cyanobacteria for lead compounds of pharmaceutical importance. The Scientific World Journal, 2012: 1-10. http://dx.doi.org/10.1100/2012/179782
51. Vijaya Baskara Sethubathi G. & Ashok Prabu V., 2012. Antibacterial activity of cyanobacterial species from Adirampattinam Coast, Southeast Coast of Palk Bay. Current Research Journal of Biological Sciences, 2: 24-26.
52. Zainuddin E.N., Mundt S., Wegner U. & Mentel R., 2002 Cyanobacteria a potential source of antiviral substances against influenza virus. Medical Microbiology and Immunology, 191: 181-182. http://dx.doi.org/10.1007/s00430-002-0142-1